RT Journal Article
T1 Xerostomia and Salivary Flow in Patients Taking Antihypertensive Drugs
A1 Ramírez Martínez-Acitores, Lucía
A1 Hernández Ruiz de Azcárate, Fernando
A1 Casañas, Elisabeth
A1 Serrano Valle, Julia
A1 Hernández Vallejo, Gonzalo
A1 López-Pintor Muñoz, Rosa María
AB The aims of this systematic review are (1) to compare the prevalence of xerostomia and hyposalivation between patients taking antihypertensive drugs with a control group (CG), (2) to compare salivary flow rate between patients treated with a CG, and (3) to identify which antihypertensives produce xerostomia. This systematic review was carried out according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. To evaluate methodological quality of the eligible studies Cochrane Collaboration tool for assessing the risk of bias for clinical trials and the modified Newcastle–Ottawa scale case-control studies were used. The databases were searched for studies up to November 19th 2019. The search strategy yielded 6201 results and 13 publications were finally included (five clinical trials and eight case-control studies). The results of the included studies did not provide evidence to state that patients taking antihypertensives suffer more xerostomia or hyposalivation than patients not taking them. With regard to salivary flow, only two clinical studies showed a significant decrease in salivary flow and even one showed a significant increase after treatment. The case–control studies showed great variability in salivary flow, but in this case most studies showed how salivary flow is lower in patients medicated with antihypertensive drugs. The great variability of antihypertensive drugs included, the types of studies and the outcomes collected made it impossible to study which antihypertensive drug produces more salivary alterations. The quality assessment showed how each of the studies was of low methodological quality. Therefore, future studies about this topic are necessary to confirm whether antihypertensive drugs produce salivary alterations.
PB MDPI
SN 1660-4601
YR 2020
FD 2020
LK https://hdl.handle.net/20.500.14352/6619
UL https://hdl.handle.net/20.500.14352/6619
LA eng
DS Docta Complutense
RD 3 may 2024